Physician profile
Richard E Kinard
NPI 1396793089
$169.62
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.98 · 2020: $27.21 · 2021: $102 · 2022: $23.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $77.63 | 2021 | |
| Boston Scientific Corporation | $51.03 | 2020-2022 | |
| Vertos Medical, INC. | $23.98 | 2021 | |
| Stryker Corporation | $16.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$711,616.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kinard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.